Literature DB >> 15545993

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice.

Massimiliano Mazzone1, Cristina Basilico, Silvia Cavassa, Selma Pennacchietti, Mauro Risio, Luigi Naldini, Paolo M Comoglio, Paolo Michieli.   

Abstract

Scatter factor (SF), also known as hepatocyte growth factor, is ubiquitously present in the extracellular matrix of tissues in the form of an inactive precursor (pro-SF). In order to acquire biological activity, pro-SF must be cleaved by specific proteases present on the cell surface. The mature form of SF controls invasive cues in both physiological and pathological processes through activation of its receptor, the Met tyrosine kinase. By substituting a single amino acid in the proteolytic site, we engineered an unprocessable form of pro-SF (uncleavable SF). Using lentivirus vector technology, we achieved local or systemic delivery of uncleavable SF in mice. We provide evidence that (a) uncleavable SF inhibits both protease-mediated pro-SF conversion and active SF-induced Met activation; (b) local expression of uncleavable SF in tumors suppresses tumor growth, impairs tumor angiogenesis, and prevents metastatic dissemination; and (c) systemic expression of uncleavable SF dramatically inhibits the growth of transplanted tumors and abolishes the formation of spontaneous metastases without perturbing vital physiological functions. These data show that proteolytic activation of pro-SF is a limiting step in tumor progression, thus suggesting a new strategy for the treatment or prevention of the malignant conversion of neoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545993      PMCID: PMC525743          DOI: 10.1172/JCI22235

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development.

Authors:  H Takayama; W J La Rochelle; M Anver; D E Bockman; G Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Production and activation of hepatocyte growth factor in acute renal failure.

Authors:  K Sugimura; T Goto; K Tsuchida; Y Takemoto; T Kim; T Kishimoto
Journal:  Ren Fail       Date:  2001 May-Jul       Impact factor: 2.606

3.  Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.

Authors:  Mark Peek; Paul Moran; Nerissa Mendoza; Dineli Wickramasinghe; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2002-10-07       Impact factor: 5.157

4.  Roles of hepatocyte growth factor and its receptor Met during gastric ulcer healing in rats.

Authors:  A Schmassmann; C Stettler; R Poulsom; N Tarasova; C Hirschi; B Flogerzi; K Matsumoto; T Nakamura; F Halter
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

5.  Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer.

Authors:  D Naka; T Ishii; Y Yoshiyama; K Miyazawa; H Hara; T Hishida; N Kidamura
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

6.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

Review 7.  The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis.

Authors:  R Zarnegar; G K Michalopoulos
Journal:  J Cell Biol       Date:  1995-06       Impact factor: 10.539

8.  The hepatocyte growth factor regulatory factors in human breast cancer.

Authors:  Christian Parr; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

9.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

10.  Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors.

Authors:  F Galimi; G P Bagnara; L Bonsi; E Cottone; A Follenzi; A Simeone; P M Comoglio
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  34 in total

Review 1.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

2.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.

Authors:  Gregory A Watson; Xinglu Zhang; Michael T Stang; Ryan M Levy; Pierre E Queiroz de Oliveira; William E Gooding; James G Christensen; Steven J Hughes
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 3.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

Review 4.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Authors:  Cassie J Liu; Douglas S Jones; Ping-Chuan Tsai; Abhishek Venkataramana; Jennifer R Cochran
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

Review 6.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

7.  Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.

Authors:  Daniel Kirchhofer; Michael T Lipari; Lydia Santell; Karen L Billeci; Henry R Maun; Wendy N Sandoval; Paul Moran; John Ridgway; Charles Eigenbrot; Robert A Lazarus
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

Review 8.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

Review 9.  Targeting the Met signaling pathway in renal cancer.

Authors:  Alessio Giubellino; W Marston Linehan; Donald P Bottaro
Journal:  Expert Rev Anticancer Ther       Date:  2009-06       Impact factor: 4.512

10.  Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.

Authors:  Nikki Cheng; Anna Chytil; Yu Shyr; Alison Joly; Harold L Moses
Journal:  Mol Cancer Res       Date:  2008-10       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.